The 2007 Accreditation Council for Pharmacy Education (ACPE) Accreditation Standards and Guidelines for the Professional Program in Pharmacy delineate new expectations for experiential education within curricula and include guidance on the development and conduct of Pharmacy Practice Experiences. The American College of Clinical Pharmacy (ACCP) Educational Affairs Subcommittee C developed a position statement to further delineate the views of ACCP on factors necessary to meet contemporary standards for doctoral education in pharmacy and to provide guidance to our membership on how to implement the new standards. This White Paper provides explanation and supporting documentation for positions on quantitative and qualitative aspects of experiential education, as well as requirements for practice sites, preceptor roles, qualification, credentialing, and development and assessment of student performance.

A B S T R AC T The purpose of this project was to determine the validity of peer and self-evaluations of class participation compared to professors' class participation grades. Students (N = 96) evaluated themselves and their classmates on class participation on a four-point scale and students were required to assign grades in a normalized distribution. Relative to faculty evaluations, the bias and precision of the peer grades were 0.48 points and 36.3 per cent (p < 0.05) and self-evaluations scores were Ϫ0.48 and 77.5 per cent (p < 0.05). There was no correlation between a student's grade point average and his/her opinion of this process (R = 0.02). Students did not like peer assessment using forced distribution of grades. K E Y WO R D S : faculty assessment and class participation, peer assessment, self-assessment

These results indicate that systemic and inhaled corticosteroids are commonly used by practitioners for the prevention or treatment of BPD despite a recommendation against the routine use of systemic corticosteroids by the American Academy of Pediatrics' (AAP) Committee on Fetus and Newborn and the Canadian Paediatric Society's Fetus and Newborn Committee from February 2002.

BACKGROUND Safety and efficacy issues regarding over-the-counter cough and cold (CAC) products for use in children have surfaced. Late in 2007 the FDA began reviewing CAC product status for use in children under 6 years old. OBJECTIVE In regards to CAC products for children &lt; 6 years old, to determine pharmacists: 1) comfort level in recommending; 2) attitudes towards behind-the-counter (BTC) status; and 3) level of support for BTC status. An additional objective was to determine how frequently pharmacists were asked for CAC product recommendations for children METHODS Georgia Pharmacy Association members (2,045) were invited to anonymously participate in a self-administered online survey from January 3 – Feb 6, 2008. Topic areas included demographics, comfort in recommending CAC, and BTC status. RESULTS Most responding pharmacists (99.1%) feel pediatric CAC medicine safety problems are due to inappropriate use. More than 50% of chain and independent pharmacists were asked to recommend CAC medicines for children during cold/flu season once a day or less, and 79% reported counseling on less than 50% of total CAC sales. The majority of pharmacists felt comfortable recommending CAC medications when thinking of both safety and efficacy. Most pharmacists supported a BTC condition of sale for children under two for decongestants, antihistamines, and antitussives, and for decongestants and antitussives for children between 2 and 5 years old. CONCLUSIONS Most pharmacists indicate comfort in recommending CAC despite lack of evidence for safety or efficacy and support BTC status. Pharmacist education on this topic would be useful.